Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer

Background: Prostate cancer persisting in the primary site after systemic therapy may contribute to emergence of resistance and progression. We previously demonstrated molecular characteristics of lethal cancer in the prostatectomy specimens of patients presenting with lymph node metastasis after ch...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Prostate cancer and prostatic diseases 2015-09, Vol.18 (3), p.276-280
Hauptverfasser: Zurita, A J, Pisters, L L, Wang, X, Troncoso, P, Dieringer, P, Ward, J F, Davis, J W, Pettaway, C A, Logothetis, C J, Pagliaro, L C
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Prostate cancer persisting in the primary site after systemic therapy may contribute to emergence of resistance and progression. We previously demonstrated molecular characteristics of lethal cancer in the prostatectomy specimens of patients presenting with lymph node metastasis after chemohormonal treatment. Here we report the post-treatment outcomes of these patients and assess whether a link exists between surgery and treatment-free/cancer-free survival. Methods: Patients with either clinically detected lymph node metastasis or primaries at high risk for nodal dissemination were treated with androgen ablation and docetaxel. Those responding with PSA concentration
ISSN:1365-7852
1476-5608
DOI:10.1038/pcan.2015.23